ARAmanda Ribeiro Rangel

Amanda Ribeiro Rangel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Amanda Ribeiro Rangel has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Efficacy and Safety of Mogamulizumab for Cutaneous T-Cell Lymphomas: A Systematic Review and Meta-Analysis

    by Ayomide Lawal, Amanda Ribeiro Rangel, Advait Raja, Maria Antônia Costa Cruz Akabane, Nathália Veloso Lana, Falaknaz Saleem, Ana Paula Pedroso Junges, Kelen Klein Heffel


  • What is on the Horizon Beyond Platinum and Immunotherapy for Patients With Advanced Non–Small Cell Lung Cancer Without Actionable Genomic Aberrations?

    by Amanda Ribeiro Rangel, Gabriel Cavalcante Lima Chagas, Rafael Cavalcante Lima Chagas, Badi El Osta

    Non–small cell lung cancer (NSCLC) remains the leading cause of cancer-related death worldwide. While targeted therapy and immunotherapy have transformed first-line management, most patients without actionable genomic alterations (AGAs) will experience disease progression within the first year of their initial treatment. Here, we review pivotal trials, emerging strategies, challenges, and unmet needs for patients with advanced NSCLC without AGAs. Docetaxel with or without ramucirumab is the standard second-line therapy for patients who have progressed after platinum-based chemotherapy and immunotherapy. Targeted therapy is only suitable for patients with specific AGAs. Understanding the hallmarks of cancer immune evasion is key to developing new strategies beyond chemoimmunotherapy. The combination of antiangiogenic agents with immune checkpoint inhibitors (ICIs) has shown mixed results after progression on platinum and ICI. Bispecific antibodies, particularly ivonescimab, have shown encouraging early efficacy in this space. Artificial intelligence–driven pathomics and radiomics tools may help to refine treatment selection in the future. Chimeric antigen receptor T-cell therapy remains investigational. Patients with advanced NSCLC without AGAs who progressed after chemoimmunotherapy have limited treatment options. Novel therapies such as specific antibodies have shown promising results. Future progress will depend on the development of predictive biomarkers and understanding the mechanisms of resistance to ICIs to guide drug development.


  • Doppler ultrasound versus computed tomography angiography prior to deep inferior epigastric perforator flap breast reconstruction: An updated systematic review and meta-analysis

    by Bernardo Gabriele Collaco, Raquel Nogueira, Pedro Lucas Machado Magalhães, Syed Ali Haider, Gabriel Cavalcante Lima Chagas, Amanda Rangel, Bruno Lins de Souza, Alessandra Marjorye Maia Leitão, Adekunle I. Elegbede


  • Effectiveness and Safety of Single Antiplatelet Therapy with P2Y12 Inhibitor Monotherapy versus Dual Antiplatelet Therapy After Percutaneous Coronary Intervention for Acute Coronary Syndrome: A Systematic Review and Meta-Analysis

    by Federal University of Ceará, Gabriel Chagas, Rafael Chagas, Amanda Rangel

    Review question / Objective: What are the effects of single antiplatelet therapy with P2Y12 inhibitor monotherapy versus dual antiplatelet therapy after percutaneous coronary intervention for acute coronary syndrome? Condition being studied: Antiplatelet therapy after percutaneous coronary intervention for acute coronary syndrome. Information sources: The databases will be Medical Literature Analysis and Retrieval System Online (MEDLINE), Excerpta Medica Database (Embase), and Cochrane Library. Searches were conducted on July 25, 2022 and will be updated on August 25, 2022. There will be no language or publication period restrictions.


  • Open Access

    COVID-19 in China, Italy and the United States of America: a short review

    by Amanda Ribeiro Rangel, Luísa Macambira Noronha, Gabriel Cavalcante Lima Chagas, Gdayllon Cavalcante Meneses, Geraldo Bezerra da Silva Júnior, Roberto da Justa Pires Neto, Elizabeth De Francesco Daher

    In December 2019, a novel coronavirus was discovered and associated with a cluster of pneumonia of unknown cause in China. SARS-CoV-2 rapidly spread and is now characterized as a pandemic. The objective of this study is to discuss COVID-19 general features, including epidemiology, transmission, control measures, virology, diagnosis, clinical characteristics and radiological and laboratory results. In this context, literature was assessed to compare the three most affected countries in Asia, Europe and Americas on March 31, 2020. The main form of transmission is human-to-human by respiratory secretions, and studies indicated substantial involvement of asymptomatic patients in this process. COVID-19 patients are predominantly men and may present multiple symptoms, especially fever and cough. Arterial hypertension and diabetes mellitus were the most common comorbidities. Worse outcomes are associated with increased age, comorbidities, and complications. Abnormalities in computed tomography of the chest are frequent, with pulmonary ground-glass opacity and bilateral patchy shadowing as the most common patterns, but a significant percentage of patients do not present any findings at time of admission. Laboratory results often present lymphocytopenia, increased neutrophils and platelet counts, erythrocyte sedimentation rate, lactate dehydrogenase, C-reactive protein, ferritin, total bilirubin, aspartate aminotransferase, alanine aminotransferase, creatinine, creatine phosphokinase, myoglobin, glucose and cytokines. Although radiological findings and laboratory results presented similarities in China, Italy and USA, case-fatality rates can be conflicting suggesting, therefore, the need for studies according to each region.


  • Open Access

    COVID-19 and Kidney: a narrative review

    by Gabriel Cavalcante Lima Chagas, Amanda Ribeiro Rangel, Luisa Macambira Noronha, Geraldo Bezerra da Silva Jr., Gdayllon Cavalcante Meneses, Alice Maria Costa Martins, Elizabeth De Francesco Daher

    COVID-19 is a pandemic associated with systemic clinical manifestations. In this study, we aimed to present a narrative review on kidney involvement in COVID-19. Kidney involvement could be derived from direct cytopathic effects, immunological mechanisms, indirect effects on renal tissue through other mediators, and dysfunction or injury of other organs. The evolution of COVID-19 may be complicated with acute kidney injury (AKI) in a significant percentage of patients, and renal dysfunction seems to be associated with worse prognosis. Patients with chronic kidney disease (CKD) seem to be more susceptible to the severe forms of COVID-19. Patients with renal replacement therapy (RRT) are also a vulnerable population as consequence of their advanced age, underlying comorbidities, impaired immune response, and clustering in hemodialysis centers, with requirements for frequent contact with healthcare services. Kidney transplant patients may be at high-risk due to long-term immunosuppression and comorbidities, hence, managing immunosuppression is imperative. Lastly, renal replacement therapy may be required during COVID-19, and different modalities are discussed based on clinical findings and laboratorial aspects. Therefore, COVID-19 seems to affect kidney by different mechanisms, which contributes for AKI development and increases the severity of the disease. Also, patients with CKD and kidney transplant recipients are at higher risk for COVID-19 and mortality.